JCHOR
Journal of Current Hematology & Oncology Research

The Journal of Current Hematology & Oncology Research regularly publishes internationally qualified research in hematology and oncology within the current scholarly knowledge.

ISSN: Active
eISSN: 2980-0854
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Original Article
Follow-up of patients given isoniazid prophylaxis in multiple myeloma patients underwent autologous stem cell transplantation
Abstract
Aims: With the developments in recent years, multiple myeloma (MM) a plasma cell discrazy has become a disease whose life expectancy is expressed in 10 years. Stem cell transplantation still maintains its place in this disease and post-transplant prophylaxis is important. One of these is antituberculosis prophylaxis. We wanted to introduce this barren subject.
Methods: A retrospective screening of patients with MM who were started on isoniazid (INH) prophylaxis and underwent autologous stem cell transplantation was planned.
Results: Antituberculosis prophylaxis was given to 25 patients (6.5%) out of 380 MM transplant patients. PPD skin test was positive in 20 of the patients who were given INH prophylaxis. 15 patients had pulmonary findings compatible with latent tuberculosis infection. Ten patients had both. No patients progressed to active tuberculosis. There was no difference between those who used INH/not in terms of obtaining CR or VGPR and other responses (p=0.220). And there was no survival difference between INH users and others.
Conclusion: Follow-up of patients receiving INH prophylaxis is also important. Histopathological findings obtained with autopsy of myeloma patients who died with pneumonia after autologous transplantation with INH prophylaxis will answer the question of whether it was tuberculosis.

Keywords : Myeloma, transplantation, INH prophylaxis

Download Article


1. Howlader N, Noone AM, Krapcho m. SEER cancer statistics review,1975-2013 National Cancer Institute Web site. 2015.
2. Tsai, Chun-Kuang, et al. Risk and impact of tuberculosis in patientswith multiple myeloma. Lymphoma. 2017;58(11):2598-2606.
3. Society AT. Targeted tuberculin testing and treatment of latenttuberculosis infection. Am J Respir Crit Care Med. 2000;(161):221-247.
4. Christopeit M, Maximilian C, Schmidt Hieber M, et al. Prophylaxis,diagnosis and therapy of infections in patients undergoing high-dose chemotherapy and autologous haematopoietic stem celltransplantation. 2020 update of the recommendations of the infectiousdiseases working party (AGIHO) of the German society of hematologyand medical oncology (DGHO). Ann Hematol. 2021;100(2):321-336.
5. Raje NS, Anaissie E, Kumar SK, et al. Consensus guidelines andrecommendations for infection prevention in multiple myeloma: areport from the international myeloma working group. Lancet. 2022;9(2):143-161.
6. Gitman M, Ju V, Nguyen T, Chen C, Rotstein C. Evaluation of a routinescreening program with tuberculin skin testing on rates of detectionof latent tuberculosis infection and prevention of active tuberculosisin patients with multiple myeloma at a Canadian cancer centre. CurrOncol. 2020;27(3):e246-e250
7. Geisler JG. “2, 4 Dinitrophenol as medicine. Cells. 2019;8(3):280.
8. Fernández GI, Ribera JM, Sabater LA. Tuberculosis duringlenalidomide maintenance in a patient with multiple myeloma. MedClin. 2021;156(5):258-259.
Article available in :
Volume 2, Issue 3, 2024
Page : 63-66
https://doi.org/10.51271/JCHOR-0040
Article Information
Received : 26 Şub 2024
Accepted : 07 Nis 2024
Published : 01 Ağu 2024
Corresponding Author :

Gülşah Akyol: Department of Hematology, Faculty of Medicine, Erciyes University, Kayseri, Türkiye

[email protected]
Citation : Akyol G, Keklik M, Kaynar L, Ünal A. Follow-up of patients given isoniazid prophylaxis in multiple myeloma patients underwent autologous stem cell transplantation. J Curr Hematol Oncol Res. 2024;2(3):63-66.

Read: 312
Cited: 0
Download : 330
_Footer